Value Added Services in Cardiometabolic Diseases -- Payer views
Pharma's Value-Added Services (VAS) in cardiometabolic disease are not universally appreciated – why? Too often, useful programmes to monitor, educate and support patients are quietly dropped post launch. No wonder there is a widespread cynical view among payers that many ""beyond the pill"" support services are little more than a marketing ploy. How can Pharma get back on track and deliver sustained VAS that innovatively support long-term cardiometabolic disease patients, change behaviour and build trust with payers? Value-added Services in Cardiometabolic Diseases meets head-on the current criticism of many VAS initiatives, and through the hard-hitting insights of senior US and EU payers, clearly identifies the key VAS design, development and areas for improvement that industry needs to address.
Reasons to Purchase
Answering key questions:
Reasons to buy this report
VAS have become a standard feature of pharma's outreach and companies can point to a raft of monitoring, education and health support services that have made a real impact. So why are payers sceptical and how is that impacting pharma's prospects? Short lived VAS are not building trust with payers or fully meeting the long-term needs of patients – especially in chronic conditions such as diabetes. It can be better. In this report experienced US and EU payers identify what good, on-target VAS look like, how working with payers can lead to better VAS solutions and how sharing outcomes data can help prove product value to a company's commercial benefit.
This report will enable you to:
Plan VAS into the product lifecycle to support patients with chronic cardiometabolic diseases
Leverage real world VAS outcomes data to support value claims with payers
Work collaboratively with payers to design innovative VAS programmes
Learn why working with trusted independent 3rd parties to deliver VAS will gain payer approval
Innovate to address non-adherence in a patient-centric way
Understand how US and EU5 payers' views of VAS vary and nuance your programmes to meet local conditions
Table of Contents
Research methodology and objectives
Experts interviewed for this report
Definitions and overview
What are cardiometabolic diseases?
What are value-added services?
The role of value-added services in cardiometabolic diseases
Key insights on the role of value-added services in cardiometabolic diseases
The challenge of behavioural change
Do VAS influence pricing & reimbursement decisions?
Types of value-added services
Table: How payers rate different types of VAS
Education and disease management
Services that support adherence and compliance
VAS that connect patients with HCPs
Reminders to take medication
Figure: Medication reminder Apps
Branded versus unbranded VAS
Pharma versus third party providers
Pharma collaboration with technology companies for cardiometabolic VAS
Case study: Roche acquisition of mySugr
Case study: Novo Nordisk's Cornerstones4Care, powered by Glooko
Opportunities for new VAS in cardiometabolic disease
Key insights on opportunities for new VAS
What payers want from VAS
Evidence of improved patient outcomes
Figure: Increasing the value-proposition of VAS
Real-world data that doctors can access
Changing behaviour is a key objective
Collaboration with payers to develop VAS
Harnessing new technology for VAS
The top opportunities for pharma
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.